Skip to main content

Bioinformatics Platforms Market is expanding with Dassault Systemes SE acquiring Medidata Solutions to take leverage of Medidata’s cloud-based services to help the development of therapeutic innovations

 


Developed regions such as North America, typically the U.S. have shown the most promising signs when it comes to the bioinformatics platforms market. This is due to high adoption of new and advanced technology, which is complemented by continuous research and development activates in the region. Similarly, Asia Pacific is witnessing increased interest in the field of bioinformatics platforms due to the presence of skilled personnel.

Bioinformatics Platforms are collections of software applications designed to facilitate the analysis of biological information. The applications and their main functions are divided into three categories, these are Cloning Lines of Action, Gene Regulation, and Gene Function. They all can be combined into one application for better functionality. However, the applications vary depending on the needs of the user and the complexity of the job. Bioinformatics is widely used in research and development activities for either drug discovery, clinical diagnostics, or personalized medicine. Such thorough and highly advanced research activities require collaborative work, in order to leverage the expertise of both private and public organizations. Recently, in October 2020, The Walther Cancer Foundation invested around US$ 11 million to expand collaborative bioinformatics cancer research with Indiana University and Purdue University. Similarly, in January 2021, Curie-Cancer entered into a bioinformatics partnership deal with GenoSplice Technology for the application of cancer genomics. Such partnership and collaboration activities can stimulate growth of the bioinformatics platforms market.

Bioinformatics platforms are usually developed using applications written in C++. The source code is made human-readable to allow users to quickly analyze the data and manipulate it. Examples of these applications include the Illumina Genomics Platform, Gene Array Expression Profiling Software, and Genomics Data Migration Tool. In the recent past, the demand for nucleic acid and protein sequencing has increased massively. This is due to the fact that sequencing cost has reduced substantially, which is complemented by technological advancements. Such positive factors are also augmenting growth of the bioinformatics platforms market.

Recently, in June 2019, Dassault Systemes SE, a French software company, acquired Medidata Solutions, a provider for SaaS-based clinical development software, for US$ 5.8 billion with the aim to take leverage of Medidata’s cloud-based services to help the development of therapeutic innovations and clinical operations performance for pharmaceutical companies.

Good bioinformatics applications should be open source. This means the software should have a collaborative development plan and be collaboratively supported. Currently, there are many open-source applications available. To see what applications are currently out there check out the Bioinet website. Despite all these positive factors, the bioinformatics platforms market is hindered by a lack of well-defined standards and common data formats for the integration of data. Besides, the low availability of user-friendly tools at competitive prices can restrain growth of the bioinformatics platforms market.

 

Comments

Popular posts from this blog

Virology Testing Market Detailed In New Research Report 2023

  Virology testing consist of diagnostic methods that help in early detection of the disease such as hepatitis, influenza, HIV, sexually transmitted disease, RCV, and other viral associated disease. Virology testing examines for detection of viral antigens, nucleic acids, and antibodies in the given sample in order to confirm the presence of particular viral infection. There are more than 100 viral diseases identified. Virology Testing Market- Market Dynamics Virology testing market is projected to witness significant growth during forecast period with rising prevalence of virus originated diseases such as flu, hepatitis, AIDS, and STDs, Ebola, Influenza based viral infections, severe acute respiratory syndrome from coronavirus, hemorrhagic fever etc. across world. Early and fast diagnosis of virus infection is very essential to start treatment course. According to the World Health Organization (WHO), January 2018 factsheet, all types of influenza in combination causes annual...

Epidermolysis Bullosa Therapeutics Market Is Booming Worldwide 2023-2028

  Epidermolysis bullosa is a group of rare inherited skin disorders that causes the skin to become very fragile. Any trauma or friction to the skin can cause painful blisters. The symptoms of epidermolysis bullosa include skin that blisters easily, blisters on hands and soles of the feet, thickened skin that may be scarred or change color over time, and thickening of the skin and nails. There are three types of epidermolysis bullosa which includes: ·          Epidermolysis bullosa simplex (EBS) – the most common type, which can range from mild, with a low risk of serious complications to severe ·          Dystrophic epidermolysis bullosa (DEB) – which can range from mild to severe ·          Junctional epidermolysis bullosa (JEB) – a rare form of epidermolysis bullosa that ranges from moderate to severe The type reflects where on the body the blistering ...

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Analysis

  A primary driver for this market is the worldwide increase in occurrence of diabetes and cancer, across all age groups. According to the World Health Organization (WHO) 2018 statistics, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. Moreover according to the World Health Organization cancer factsheet 2018, Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018.  Furthermore, increasing old age population is another driver, which is anticipated to create a high growth scenario for the market. As per the World Population Prospects 2019 revision, the number of people aged 80 years or over is projected to be triple, from 143 million in 2019 to 426 million in 2050. Alternatively, factors restraining the market are complications and risks associated with the treatment including diarrhea, nausea, hair loss, vomiting, severe infections, infertility, and heart complications....